Coegin Pharma is a Swedish biotech company with groundbreaking projects in hair growth, myocardial infarction, leukemia, and skin cancer.

Our business idea is to develop products in attractive areas where treatments are lacking, there is significant commercial value, and an opportunity for early exit.

ABOUT US

Our portfolio companies

With our three portfolio companies, we have a pipeline consisting of both dermacosmetic product candidates for stimulating hair growth and drug candidates in leukemia and skin cancer.

Follicum focuses on the development of a new and pioneering product line that stimulates hair growth.

Read more on follicum.com

Avexxin Oncology focuses on the development of new innovative drugs in inflammation-driven cancer.

Read more on avexxinoncology.com

Reccura Therapeutics focuses on being able to offer a unique and well-tolerated treatment for both actinic keratosis and basal cell carcinoma.

Read more on reccuratherapeutics.com

Our research

In our total project portfolio, we currently have six projects: five drug candidates and a product series in dermacosmetics. What the projects have in common is that they are based on two unique validated technology platforms resting on solid research and collaborations with pioneering and internationally recognized researchers and academics.

Latest news

Press releases

More press releases

Reports

More reports

Upcoming events

More events

Video presentations

See more

Team Coegin

Our management team has extensive experience in drug development, commercialization and business scale-up.

Meet the team
Jens Eriksson

CEO

Lars Bukhave Rasmussen

CFO

John Zibert

CMO